Pharmacyclics falls after presentation

|By:, SA News Editor

Shares of Pharmacyclics (PCYC -1.6%) are lower in afternoon trading after the company's presentation at the JPMorgan Healthcare Conference.

Ibrutinib highlights from the "conclusions" slide: Drug "demonstrated safety, tolerability, and durability of response at ≥ one year ... in treatment naive and relapsed/refractory CLL/SLL;" serious AEs decreased after one year of treatment; median DOR not yet reached in extension study.

See also: PCYC notifies investors of relevant changes to NCCN Clinical Practice Guidelines

For more on ibrutinib (Imbruvica) in CLL/SLL, see here.